NovaBay Pharmaceuticals Inc Market Cap ($32.22 Million)
Market Cap & Net Worth: NovaBay Pharmaceuticals Inc (NBY)
NovaBay Pharmaceuticals Inc market cap. NovaBay Pharmaceuticals Inc (NYSE MKT:NBY) has a market capitalization of $32.22 Million ($32.22 Million) as of November 4, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #23314 globally and #5094 in its home market, demonstrating a -13.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NovaBay Pharmaceuticals Inc's stock price $1.21 by its total outstanding shares 26625029 (26.63 Million). Also see NovaBay Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
NovaBay Pharmaceuticals Inc Market Cap History (2015–2026)
NovaBay Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $65.88 Billion to $32.22 Million (-57.46% CAGR). Check NBY stock price and chart for real-time trading data and today's change.
NovaBay Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NovaBay Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NovaBay Pharmaceuticals Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.64x
NovaBay Pharmaceuticals Inc's market cap is 1.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $107.63 Billion | $11.90 Million | -$13.15 Million | 9046.96x | N/A |
| 2017 | $125.57 Billion | $18.23 Million | -$7.40 Million | 6888.11x | N/A |
| 2018 | $25.20 Billion | $12.51 Million | -$6.54 Million | 2014.88x | N/A |
| 2019 | $20.87 Billion | $6.60 Million | -$9.66 Million | 3163.21x | N/A |
| 2020 | $22.73 Billion | $9.93 Million | -$11.04 Million | 2288.42x | N/A |
| 2021 | $12.28 Billion | $10.20 Million | -$5.82 Million | 1203.75x | N/A |
| 2022 | $1.82 Billion | $14.40 Million | -$10.61 Million | 126.16x | N/A |
| 2023 | $190.10 Million | $10.46 Million | -$9.64 Million | 18.18x | N/A |
| 2024 | $16.00 Million | $9.78 Million | -$7.22 Million | 1.64x | N/A |
Competitor Companies of NBY by Market Capitalization
Companies near NovaBay Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see total assets of NovaBay Pharmaceuticals Inc for a full breakdown of the balance sheet.
Key companies related to NovaBay Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of NovaBay Pharmaceuticals Inc (2015–2026)
Market capitalization of NovaBay Pharmaceuticals Inc from 2015 to today. Between 2015 and today, NovaBay Pharmaceuticals Inc's market cap moved from $65.88 Billion to $ 32.22 Million, with a yearly change of -57.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $32.22 Million | -78.55% |
| 2025 | $150.17 Million | +838.44% |
| 2024 | $16.00 Million | -91.58% |
| 2023 | $190.10 Million | -89.54% |
| 2022 | $1.82 Billion | -85.21% |
| 2021 | $12.28 Billion | -45.97% |
| 2020 | $22.73 Billion | +8.91% |
| 2019 | $20.87 Billion | -17.17% |
| 2018 | $25.20 Billion | -79.93% |
| 2017 | $125.57 Billion | +16.67% |
| 2016 | $107.63 Billion | +63.37% |
| 2015 | $65.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of NovaBay Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.22 Million USD |
| MoneyControl | $32.22 Million USD |
| MarketWatch | $32.22 Million USD |
| marketcap.company | $32.22 Million USD |
| Reuters | $32.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more